Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DL81ME
|
|||
Drug Name |
ASP3082
|
|||
Drug Type |
Small molecule
|
|||
Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Astelllas
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | KRas D816V mutant (KRAS D816V) | Target Info | Degrader | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health. | |||
REF 2 | Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.